



Announcing First-in-History Human Safety Trials of Full-Body Mitochondrial Transplantation

Pleasanton, CA, April 6, 2026 -- Mitrix Bio today announced the successful completion of preliminary Phase 1 safety trials involving large infusions of transplanted mitochondria in a small group of senior participants, including attorney, futurist, and “patient 0” Clayton Rawlings, 71, and physicist, CERN experimentalist, and science fiction author John G. Cramer, 91.

The trial sequence began with Rawlings, who underwent the first infusion one week before Cramer and has gone first in each round so the team could evaluate safety before proceeding further.

Backed by a superstar team of scientists and doctors from Stanford, UCLA, Harvard, and other universities, Mitrix is the world leader in mitochondrial transplantation, developing bioreactors capable of producing mitochondria at scale using the individual’s own healthy mitochondria.

For Rawlings, participation in the trial carries both scientific and personal significance. In *Pardon the Disruption: The Future You Never Saw Coming*, published in 2013, Clayton Rawlings was already writing publicly about dramatic life extension and the emerging possibility of age reversal, years before longevity science entered the mainstream conversation. Participating now as the first human subject in this protocol, at age 71, represents a direct step into a future he was writing about more than a decade ago.



Clay Rawlings



John G. Cramer, PhD

“This is exactly the kind of breakthrough I believed was coming,” said Rawlings. “To now serve as patient zero in a trial aimed at restoring mitochondrial function is both extraordinary and deeply meaningful.”

The greatest urgency, however, surrounds Cramer, who at 91 views the pace of conventional longevity science as too slow for those who need meaningful breakthroughs now.

“Billions of dollars have been flowing into longevity startups, but most is still being spent on narrow approaches that may take decades to mature,” said Cramer. “I’m 91. I cannot wait that long. We need full body rejuvenation, and we need it now.”

The safety trials began in February with smaller doses and then escalated in carefully monitored stages, with ongoing review of blood chemistry, physical condition, and other key metrics. According to the participants and investigators, the early results showed no obvious adverse effects and supported continued advancement of the program.

The participants, calling themselves the “Mitonauts,” include several dozen scientists, entrepreneurs, doctors, and VCs, ranging in age from their 70s into their 90s. Together, they lend their experience, visibility, and support to help accelerate this technology. Initial tests were conducted by a team of physicians and scientists in Dallas, Texas, working at the Mitochondrial Transplantation Institute clinic, established under recent Right to Try 2.0 legislation.

“This work is not only about healthier aging for people our age,” Rawlings said. “There are younger people, including children with devastating diseases, who may benefit from advances like this. We are honored to serve as early test pilots for something that could eventually help many more people than ourselves.”

About Mitochondrial Transplantation

[As described in The Economist](#), Mitochondrial Transplantation is a fast-growing area of medical research focused on restoring cellular energy and function through the transfer of healthy mitochondria. For almost a decade, researchers have been exploring its potential applications across a range of conditions involving tissue injury, degeneration, and impaired cellular metabolism. After years of animal studies and small-scale human trials, the current mission is to make this therapy more scalable, more accessible, and more clinically practical. Last year [the first annual Mitochondrial Transplantation Conference](#) was organized by Northwell Health, the largest health plan in New York State.

Next Steps

The results of these safety trials will be released to a select group of hospitals and researchers. The Mitonauts plan to start efficacy trials in mid-2026.

Mitochondrial Transplantation Institute clinics, for experimental and innovative treatments, have been launched in California, Texas, Florida, and other locations. See www.mitoclinics.org.

Dr. Cramer’s forthcoming book, [How to Live Much Longer: The Mitochondrial DNA Connection](#), examines the biology, physics, and broader implications of mitochondrial transplantation for longevity. Scheduled for release May 2026.

About Mitrix

Mitrix Bio Inc. is the world leader in bioreactor-grown mitochondrial transplantation. Backed by a superstar team of scientists and doctors from Stanford, UCLA, Harvard, and other universities, plus former NASA astronauts and celebrities, Mitrix is based in Silicon Valley.

Media Contact

Tom Benson
CEO
Mitrix Bio Inc.
tom@mitrix.bio